Please login to the form below

Not currently logged in
Email:
Password:

Mesoblast

This page shows the latest Mesoblast news and features for those working in and with pharma, biotech and healthcare.

Stem cell therapy promising for rheumatoid arthritis

Stem cell therapy promising for rheumatoid arthritis

Stem cell therapy promising for rheumatoid arthritis. Mesoblast’ s phase II trial sees "impressive efficacy" in refractory patients. ... Mesoblast's MPCs are off-the-shelf, allogeneic stem cell therapies that do not rely on harvesting cells from

Latest news

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    trial; Mesoblast/Teva with allogenic mesenchymal stem cell therapy Neofuse; and Celyad's C-Cure, based on autologous cardiac stem cells.

  • Pharma deals in April 2015 Pharma deals in April 2015

    As mentioned above, Celgene had an exceptionally busy month announcing deals with Quanticel Pharmaceuticals, AZ, Agios Pharmaceuticals, Mesoblast and Northern Biologics. ... Celgene's other deals are with Agios Pharmaceuticals, Mesoblast and AZ. With

  • Medius Deal Watch table for April 2015 Medius Deal Watch table for April 2015

    49. Mesoblast / Celgene. Minority investment and option to license. stem-cell product candidates for conditions including inflammatory bowel disease and certain oncological indications.

  • Deal Watch table for October 2013 Deal Watch table for October 2013

    Commercialisation. Oralair, grass allergy sublingual tablet (pre-registration). 120. Osiris Therapeutics / Mesoblast .

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Weekly industry appointments Weekly industry appointments

    Weekly industry appointments. GSK’s CSO cell and gene therapy heads for the exit, Gelesis adds to company, Abcam appoints Peter Allen and Joseph Swedish joins Mesoblast’s board. ... Joseph Swedish joins Mesoblast’s board. Cell-based medicines group

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics